Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.9, Iss.2, 2005-04, pp. : 267-281

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007 – 2008

By Corbett Jeffrey W

Expert Opinion on Therapeutic Patents, Vol. 19, Iss. 7, 2009-07 ,pp. : 943-956

Informa Healthcare

Access to resources Recommend Favorite

Characterization of Acetyl-CoA Carboxylases in the Basal Dinoflagellate Amphidinium carterae

By Haq Saddef Bachvaroff Tsvetan R. Place Allen R.

Marine Drugs, Vol. 15, Iss. 6, 2017-05 ,pp. : 149-149

MDPI

Access to resources Recommend Favorite

Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome

Current Pharmaceutical Design, Vol. 20, Iss. 39, 2014-12 ,pp. : 6106-6113

Bentham Science Publishers

Access to resources Recommend Favorite

Stearoyl-CoA Desaturase-1 and the Metabolic Syndrome

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 3, Iss. 4, 2003-12 ,pp. : 271-280

Bentham Science Publishers

Access to resources Recommend Favorite

Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome – 11β-hydroxysteroid dehydrogenase type 1

By Stewart Paul M

Clinical Medicine, Vol. 5, Iss. 2, 2005-03 ,pp. : 142-146

Royal College Of Physicians

Access to resources Recommend Favorite